Effects of leptin on cat intestinal motility.
In a previous study, we established that leptin controls food intake and immune responses by acting on intestinal vagal chemosensitive mechanoreceptors via a functional link with interleukin-1 beta (Il-1 beta). Since the control of intestinal motility is one of the main roles of the vagal afferent fibres, we investigated the effects of leptin on intestinal electromyographic (EMG) activity which reflects intestinal motility. For this purpose, the effects of locally injected leptin on small intestine spontaneous EMG activity were studied in 23 anaesthetised cats. The EMG activity was recorded using bipolar electrodes implanted in the proximal small intestine. Leptin and Il-1 beta (0.1, 1 and 10 microg), administered through the artery irrigating the upper part of the intestine 20 min after cholecystokinin (CCK, 10 microg, I.A.), had significant (P < 0.001) excitatory effects on intestinal EMG activity. The effects of both substances were blocked by the endogenous interleukin-1 beta receptor antagonist (Il-1ra, 250 microg, I.A.), by atropine (250 microg, I.A.) and by vagotomy. In the absence of CCK, leptin and Il-1 beta had no effect on intestinal electrical activity. It can therefore be concluded that: (1) leptin is effective only after the previous intervention of CCK, (2) the enhancement of the electrical activity induced by leptin involves Il-1 beta receptors and the cholinergic excitatory pathway, (3) the modes whereby the leptin-induced enhancement of EMG activity occurs strongly suggest that these effects are due to a long-loop reflex involving intestinal vagal afferent fibres and the parasympathetic nervous system.
Gaigé
Stéphanie
S
Laboratoire de Physiologie Neurovégétative, UMR CNRS 6153, UMR INRA, Faculté des Sciences et Techniques Saint-Jérôme, Université Aix-Marseille 3, Case postale 351-352, Avenue Escadrille Normandie Niemen, 13397 Marseille Cedex 20, France.
Abysique
Anne
A
Bouvier
Michel
M
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001645:Biguanides / Q000494:pharmacology; D002415:Cats; D002766:Cholecystokinin / Q000494:pharmacology; D004386:Duodenum / Q000187:drug effects / Q000502:physiology; D004576:Electromyography; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007375:Interleukin-1 / Q000494:pharmacology; D020738:Leptin / Q000494:pharmacology*; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D014628:Vagotomy
D001645:Biguanides; D007375:Interleukin-1; D020738:Leptin; D018727:Muscarinic Antagonists; D017366:Serotonin Receptor Agonists; D013373:Substance P; D001285:Atropine; D002766:Cholecystokinin; C008846:phenyl biguanide